鼻噴新冠疫苗臨牀試驗

Nasal COVID vaccine in trials
鼻噴新冠疫苗臨牀試驗

The University of Hong Kong said on Wednesday the clinical trials of a nasal spray vaccine for COVID-19, jointly developed by the university's department of microbiology and mainland institutions, have been approved.
香港大學9月9日宣佈，該校微生物學系與內地機構聯合研發的鼻噴新冠疫苗已獲批開展臨牀試驗。

The State Key Laboratory of Emerging Infectious Diseases has been working on the vaccine with Xiamen University and Beijing Wantai Biological Pharmacy. It is the first nasal spray COVID-19 vaccine approved by China's National Medical Products Administration for clinical trials in humans.
這款疫苗由港大新發傳染病國家重點實驗室與廈門大學、北京萬泰生物藥業股份有限公司共同研發，是首款通過國家藥品監督管理局審批，獲准開展人體臨牀試驗的鼻噴式新冠疫苗。

HKU said in a statement its vaccine strategy has been selected as one of five vaccine technologies by the Ministry of Science and Technology for further evaluation.
港大在聲明中稱，這個疫苗研究項目得到科技部立項支持，是國家五個重點疫苗技術策略之一。